Sponsors

Wellcome news for Agilent

Agilent Technologies has announced that the Wellcome Trust Case Control Consortium (WTCCC) will standardise the world’s largest human genomic copy number variation (CNV) study on Agilent microarrays. Agilent has also announced that IMGM Laboratories has achieved Certified Service Provider (CSP) status for the Agilent microarray platform.

The Wellcome Trust CNV study aims to determine the genetic causes of certain widespread diseases. The samples will be processed by Oxford Gene Technology (OGT), an Agilent microarray CSP in Oxford. This is an important study of human genetic variation in common diseases, which requires high-resolution microarrays with extremely reproducible performance.

IMGM is one of Europe’s leading genomic service providers and achieved Agilent-certified status after completing training and passing a rigorous series of assessments. These included demonstrating proficiency in, for example, analysing Agilent’s 60-mer oligo microarrays using the complete Agilent system, sample quality control using the Agilent 2100 bioanalyser, sample labelling using Agilent reagents and protocols, and final data analysis using the GeneSpring bioinformatics platform.

www. agilent.com

Latest Issues

BDIAP Molecular Pathology Study Day

10 Union Street, London, SE1 1SZ
2 March, 2026

Cell & Gene Therapy 2026

Hinxton Hall Conference Centre, Wellcome Genome Campus, Hinxton, CB10 1RQ
9-10 March, 2026

USCAP 115th Annual Meeting

Henry B. González Convention Center, San Antonio, Texas, USA
21-26 March, 2026